Autoantibodies on Spinal Cord Injury

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

110 participants

Study Classification

OBSERVATIONAL

Study Start Date

2014-10-17

Study Completion Date

2018-04-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to determine the autoantibody profiles after spinal cord injury and their role in spontaneous functional recovery.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Identification of Autoantibodies and Autoantigens in the Cerebrospinal Fluid of Patients With Spinal Cord Trauma

NCT03249129

Bone Marrow Failure Trauma

WITHDRAWN

Autoimmunity And Immune Deficiency After Spinal Cord Injury: Association With Rehabilitation Outcomes

NCT04211636

Spinal Cord Trauma

NOT_YET_RECRUITING

The Neuroinflammatory Response and Biomarkers in Acute Traumatic Spinal Cord Injury

NCT03505463

Spinal Cord Injury, Acute

UNKNOWN

Autologous Bone Marrow Stem Cell Transplantation in Patients With Spinal Cord Injury

NCT01325103

Spinal Cord Injury

COMPLETED NA

Deciphering Preserved Autonomic Function After Spinal Cord Injury

NCT04493372

Spinal Cord Injuries Autonomic Imbalance Autonomic Dysreflexia +1 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Most patients experience variable degrees of functional recovery after spinal cord injury (SCI), predominantly in the first months after lesion. In SCI animal models, autoantibodies are pathogenic and their titers rise up at the time when spontaneous recovery stops. The aim of this study is to determine the autoantibody profiles after SCI and to infer their relation with functional recovery. To achieve this, autoantibody profiles, biochemical, hematological and immune-related parameters (cytokines, chemokines and growth factors) will be determined from a serum blood sample and functional recovery will be evaluated accordingly to standardized scales.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Spinal Cord Injuries

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Spinal cord injury

Patients (n=90) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed twice: after recruitment and 3 months later.

Blood collection

Intervention Type OTHER

Blood collection from the subject's arm

Controls

Control subjects (n=20) will undergo a common arm blood collection to determine autoantibody profiles in serum. This procedure will be performed only once.

Blood collection

Intervention Type OTHER

Blood collection from the subject's arm

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Blood collection

Blood collection from the subject's arm

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Traumatic or non-progressive vascular SCI
* Less than 45 days after lesion
* Any neurological level
* Complete and incomplete lesions
* If patient has been treated with glucocorticoids, it should have passed at least 7 days from the end of the treatment